サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1514170

HIV治療薬の世界市場

HIV Drugs

出版日
ページ情報
英文 164 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.08円
HIV治療薬の世界市場
出版日: 2024年07月17日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 164 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

HIV治療薬の世界市場は2030年までに445億米ドルに到達

2023年に311億米ドルと推定されたHIV治療薬の世界市場は、2023～2030年の分析期間においてCAGR 5.3%で成長し、2030年には445億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである併用HIV治療薬は、CAGR 5.2%を記録し、分析期間終了時には290億米ドルに達すると予測されます。インテグラーゼ阻害剤（INI）セグメントの成長率は、分析期間中CAGR 5.8%と推定されます。

米国市場は84億米ドル、中国はCAGR 8.8%で成長すると予測される

米国のHIV治療薬市場は2023年に84億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに97億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは8.8%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.7%と4.3%と予測されています。欧州では、ドイツがCAGR 3.4%で成長すると予測されています。

HIV治療薬-主要動向と促進要因

HIV治療薬はヒト免疫不全ウイルス（HIV）の管理と治療に革命をもたらし、かつては致命的な診断であったものが、多くの人にとって管理可能な慢性疾患へと変化しました。抗レトロウイルス療法（ART）の開発は、患者が低ウイルス量を維持し、感染リスクを軽減し、生活の質を向上させることを可能にする重要なマイルストーンでした。ARTでは通常、ヌクレオシド系逆転写酵素阻害薬（NRTI）、非ヌクレオシド系逆転写酵素阻害薬（NNRTI）、プロテアーゼ阻害薬（PI）、インテグラーゼ鎖移行阻害薬（INSTI）、エントリー阻害薬など、異なる薬剤クラスの薬剤を組み合わせて使用します。この多剤併用療法は、ウイルスが耐性を獲得するのを防ぐのに有効であり、効果的なHIV管理の重要な側面です。過去数十年の間に、より優れた有効性、より少ない副作用、簡略化された投与レジメンによるアドヒアランスの改善を提供する新薬製剤の開発において、大きな進歩がありました。

HIV治療薬市場で最も注目すべき動向の1つは、毎日の経口薬に代わる利便性の高い長時間作用型注射抗レトロウイルス薬の開拓です。毎月または隔月に投与されるこれらの注射剤は、服薬アドヒアランスの向上に役立ち、毎日の錠剤摂取に伴うスティグマを軽減します。さらに、個々の遺伝子プロファイルやウイルスの特性に合わせた治療により、治療成績を向上させる個別化医療への注目も高まっています。ナノ粒子ベースの製剤などのドラッグデリバリーシステムの革新も、HIV治療薬の薬物動態と生体内分布を改善するために研究されています。さらに、HIV治療と、ハイリスク集団に対する曝露前予防薬（PrEP）や包括的なセクシャルヘルスサービスなどの他のヘルスケアサービスとの統合により、HIVケアの範囲と有効性が拡大しています。

HIV治療薬市場の成長は、医薬品開発の技術的進歩、HIVの有病率の増加、中低所得国における治療アクセスの拡大など、いくつかの要因によってもたらされます。分子生物学とウイルス学の進歩は、新たな治療標的の発見と新規作用機序を持つ薬剤の開発を促進しています。特にサハラ以南のアフリカやその他の有病率の高い地域におけるHIVの世界の負担の増大は、HIV治療における継続的な技術革新とアクセシビリティの必要性を強調しています。エイズ救済のための大統領緊急計画（PEPFAR）や世界エイズ・結核・マラリア対策基金などの政府のイニシアティブや国際的プログラムは、資源が限られた環境におけるHIV治療薬の利用可能性を高める上で極めて重要な役割を果たしています。さらに、HIV治療に対する認識と受容の高まり、診断能力の向上が、治療の普及を後押ししています。製薬業界の研究開発へのコミットメントと戦略的パートナーシップや提携は、HIV治療薬市場の進展を後押しし続け、患者が最新かつ最も効果的な治療にアクセスできるようにしています。

調査対象企業の例（全52件）

  • AbbVie, Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Emcure Pharmaceuticals Pvt., Ltd.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • Hetero Drugs Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • ViiV Healthcare

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP-6176

Global HIV Drugs Market to Reach US$44.5 Billion by 2030

The global market for HIV Drugs estimated at US$31.1 Billion in the year 2023, is expected to reach US$44.5 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2023-2030. Combination HIV Medicines, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$29.0 Billion by the end of the analysis period. Growth in the Integrase Inhibitors (INIs) segment is estimated at 5.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$8.4 Billion While China is Forecast to Grow at 8.8% CAGR

The HIV Drugs market in the U.S. is estimated at US$8.4 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$9.7 Billion by the year 2030 trailing a CAGR of 8.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 4.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

HIV Drugs - Key Trends and Drivers

HIV drugs have revolutionized the management and treatment of Human Immunodeficiency Virus (HIV), transforming what was once a fatal diagnosis into a manageable chronic condition for many individuals. The development of antiretroviral therapy (ART) has been a significant milestone, enabling patients to maintain low viral loads, reduce transmission risks, and improve their quality of life. ART typically involves a combination of medications from different drug classes, including nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transfer inhibitors (INSTIs), and entry inhibitors. This multi-drug approach helps to prevent the virus from developing resistance, which is a critical aspect of effective HIV management. Over the past few decades, significant advancements have been made in developing new drug formulations that offer better efficacy, fewer side effects, and improved adherence through simplified dosing regimens.

One of the most notable trends in the HIV drugs market is the development of long-acting injectable antiretrovirals, which provide a convenient alternative to daily oral medications. These injectables, administered monthly or bi-monthly, help to improve adherence and reduce the stigma associated with daily pill intake. Additionally, there is a growing focus on personalized medicine, with treatments tailored to individual genetic profiles and viral characteristics, enhancing therapeutic outcomes. Innovations in drug delivery systems, such as nanoparticle-based formulations, are also being explored to improve the pharmacokinetics and biodistribution of HIV drugs. Furthermore, the integration of HIV treatment with other healthcare services, such as pre-exposure prophylaxis (PrEP) for high-risk populations and comprehensive sexual health services, is expanding the reach and effectiveness of HIV care.

The growth in the HIV drugs market is driven by several factors, including technological advancements in drug development, the increasing prevalence of HIV, and expanding access to treatment in low- and middle-income countries. Advances in molecular biology and virology have facilitated the discovery of new therapeutic targets and the development of drugs with novel mechanisms of action. The rising global burden of HIV, particularly in sub-Saharan Africa and other high-prevalence regions, underscores the need for continued innovation and accessibility in HIV treatment. Government initiatives and international programs, such as the President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis and Malaria, play a pivotal role in increasing the availability of HIV drugs in resource-limited settings. Additionally, the growing awareness and acceptance of HIV treatment, coupled with improved diagnostic capabilities, are driving higher treatment uptake. The pharmaceutical industry's commitment to research and development, along with strategic partnerships and collaborations, continues to fuel progress in the HIV drugs market, ensuring that patients have access to the latest and most effective treatments.

Select Competitors (Total 52 Featured) -

  • AbbVie, Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Emcure Pharmaceuticals Pvt., Ltd.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • Hetero Drugs Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • ViiV Healthcare

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • HIV Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Global Burden of HIV in High-Prevalence Regions Spurs Demand for Effective Treatments
    • Advances in Antiretroviral Therapy Propel Market Growth
    • Long-Acting Injectable Antiretrovirals Drive Adoption and Improve Adherence
    • Personalized Medicine Approaches Strengthen Business Case for Tailored HIV Treatments
    • Innovations in Drug Delivery Systems Generate Demand for Improved Formulations
    • Integration of HIV Treatment with Comprehensive Sexual Health Services Spurs Market Expansion
    • Government Initiatives and International Programs Enhance Market Accessibility
    • Growing Focus on PrEP (Pre-Exposure Prophylaxis) Expands Market Opportunities
    • Advances in Molecular Biology and Virology Propel Discovery of Novel Therapeutic Targets
    • Increased Availability of Generic HIV Drugs Generates Market Competition
    • Improved Diagnostic Capabilities Accelerate Demand for HIV Treatments
    • Rising Awareness and Acceptance of HIV Treatment Drive Adoption Rates
    • Enhanced Healthcare Infrastructure in Developing Regions Sustains Market Growth
    • Development of Combination Therapies Expands Market Potential
    • Addressing Drug Resistance Challenges Drives Continuous Innovation in HIV Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World HIV Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for HIV Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for HIV Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for HIV Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Combination HIV Medicines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Combination HIV Medicines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Combination HIV Medicines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Integrase Inhibitors (INIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Integrase Inhibitors (INIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Integrase Inhibitors (INIs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • JAPAN
    • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • CHINA
    • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • EUROPE
    • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for HIV Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for HIV Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for HIV Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • FRANCE
    • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: France Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: France 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • GERMANY
    • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: UK 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for HIV Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for HIV Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for HIV Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • INDIA
    • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: India Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: India 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for HIV Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for HIV Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for HIV Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for HIV Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for HIV Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for HIV Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • AFRICA
    • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

IV. COMPETITION